Accès gratuit
Numéro
Med Sci (Paris)
Volume 20, Numéro 8-9, Août-Septembre 2004
Page(s) 788 - 792
Section M/S revues
DOI https://doi.org/10.1051/medsci/2004208-9788
Publié en ligne 15 août 2004
  1. Blumberg-Mokri M. Les inventions biotechnologiques. Biofutur 2002; 218 : 42–3.
  2. Sobol H, Bignon YJ, Bonaiti C, et al. Four years analysis of cancer genetic clinics activity in France form 1994 to 1997 : a survey on 801 patients. Dis Markers 1999; 15 : 1–15.
  3. Miki Y, Swensen J, Shattuck-Eiders D, et al. A strong candidate for the breast and ovarian susceptibility gene BRCA1. Science 1994; 266 : 66–71.
  4. Wooster R, Bignell G, Lancaster J, et al. Identification of the breast cancer susceptibility gene BRCA2. Nature 1995; 378 : 789–92.
  5. Expertise collective Inserm. Risques héréditaires de cancer du sein et de l’ovaire : quelle prise en charge ? Paris : Inserm, 1998 : 636 p.
  6. Eisinger F, Alby N, Bremond A, et al. Recommendations for medical management of hereditary breast and ovarian cancer : the French National Ad Hoc Committee. Ann Oncol 1998; 9 : 939–50.
  7. American Society of Clinical Oncology. Statement of the American Society of Clinical Oncology : Genetic testing for cancer susceptibility. J Clin Oncol 1996; 14 : 1730–6.
  8. Butler D, Goodman S. French researchers take a stand against cancer gene patent. Nature 2001; 413 : 95–6.
  9. Benowitz S. French challenge to BRCA1 patent underlies European discontent. J Natl Cancer Inst 2002; 94 : 80–1.
  10. Wadman M. Testing time for gene patent as Europe rebels. Nature 2001; 413 : 443.
  11. Sevilla C, Julian-Reynier C, Eisinger F, et al. The impact of gene patents on the cost-effective delivery of care : The case of BRCA1 genetic testing. Int J Technol Assess Health Care 2003; 19 : 287–300.
  12. Sevilla C, Moatti JP, Julian-Reynier C, et al. Testing for BRCA1 mutations : A cost-effectiveness analysis. Eur J Hum Genet 2002; 10 : 599–606.
  13. Brower V. Testing, testing… testing ? Nat Med 1997; 3 : 131–2.
  14. Kaufert PA. Health policy and the new genetics. Soc Sci Med 2000; 51 : 821–9.
  15. Reynolds T. NCI-Myriad agreement offers BRCA testing at reduced cost. J Natl Cancer Inst 2000; 92 : 596.
  16. Hollon T. NIH researchers receive cut-price BRCA test. Nat Med 2000; 6 : 610.
  17. Cassier M, Gaudillière JP. Recherche, médecine et marché : la génétique du cancer du sein. Sci Soc Santé 2000; 18 : 29–49.
  18. Gold ER, Caulfield TA. The moral tollbooth : A method that makes use of the patent system to address ethical concerns in biotechnology. Lancet 2002; 359 : 2268–70.
  19. Zick CD, Smith KR, Mayer RN, Botkin JR. Genetic testing, adverse selection, and the demand for life insurance. Am J Med Genet 2000;93 : 29–39.
  20. Hoel M, Iversen T. Genetic testing when there is a mix of compulsory and voluntary health insurance. J Health Econ 2002; 21 : 253–70.
  21. Strohmenger R, Wambach A. Adverse selection and categorical discrimination in the health insurance markets: the effects of genetic tests. J Health Econ 2000; 19 : 197–218.
  22. C;ller H. Genetic testing for cancer predisposition-an ongoing debate. Lancet Oncol 2000; 1 : 118–9.
  23. Matloff ET, Shappell H, Brierley K, et al. What would you do ? Specialists’ perspectives on cancer genetic testing, prophylactic surgery, and insurance discrimination. J Clin Oncol 2000; 18 : 2484–92.
  24. Peterson EA, Milliron KJ, Lewis KE, et al. Health insurance and discrimination concerns and BRCA1/2 testing in a clinic population. Cancer Epidemiol Biomarker Prev 2002; 11 : 79–87.
  25. Julian-Reynier C, Sobol H, Sevilla C, et al. Uptake of hereditary breast/ovarian cancer genetic testing in a French national sample of BRCA1 families. Psycho- Oncology 2000; 9 : 504–10.
  26. Julian-Reynier C, Eisinger F, Chabal F, et al. Disclosure to the family of breast/ovarian cancer genetic test results : patient’s willingness and associated factors. Am J Med Genet 2000; 94 : 13–8.

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.